Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott T Tagawa

Showing results (171-180 of 208) with videos related to

Pageof 21
Sort By:
European Urology Open Science|May 11, 2022
What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their OutcomesVasileios I Sakalis, Riccardo Campi, Lenka Barreto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2017
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate CancerEmmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2023
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate CancerJamie M Sperger, Kyle T Helzer, Charlotte N Stahlfeld, et al.
Nature Communications|July 7, 2019
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signalingBrian D Robinson, Panagiotis J Vlachostergios, Bhavneet Bhinder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2023
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate CancerLisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated AntigensNeal D Shore, Matthew P Morrow, Trevor McMullan, et al.
World Journal of Urology|July 27, 2012
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?Michael Rink, Shahrokh F Shariat, Evanguelos Xylinas, et al.
Cancer Discovery|January 10, 2024
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationGian Marco Franceschini, Orsetta Quaini, Kei Mizuno, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
BJU International|September 24, 2013
Predictors of survival in patients with disease recurrence after radical nephroureterectomyLuis A Kluth, Evanguelos Xylinas, Matthew Kent, et al.
Pageof 21

Showing results (171-180 of 208) with videos related to

Sort By:
Pageof 21
European Urology Open Science|May 11, 2022
What Is the Most Effective Management of the Primary Tumor in Men with Invasive Penile Cancer: A Systematic Review of the Available Treatment Options and Their OutcomesVasileios I Sakalis, Riccardo Campi, Lenka Barreto, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 21, 2017
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate CancerEmmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2023
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate CancerJamie M Sperger, Kyle T Helzer, Charlotte N Stahlfeld, et al.
Nature Communications|July 7, 2019
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signalingBrian D Robinson, Panagiotis J Vlachostergios, Bhavneet Bhinder, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 12, 2023
Developing a Patient-Reported Outcome Measure for Radionuclide Therapy for Prostate CancerLisa M Gudenkauf, Melody N Chavez, Melinda Leigh Maconi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 26, 2020
CD8<sup>+</sup> T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated AntigensNeal D Shore, Matthew P Morrow, Trevor McMullan, et al.
World Journal of Urology|July 27, 2012
Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?Michael Rink, Shahrokh F Shariat, Evanguelos Xylinas, et al.
Cancer Discovery|January 10, 2024
Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationGian Marco Franceschini, Orsetta Quaini, Kei Mizuno, et al.
Prostate Cancer and Prostatic Diseases|August 12, 2024
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 studyJulie N Graff, Christopher J Hoimes, Winald R Gerritsen, et al.
BJU International|September 24, 2013
Predictors of survival in patients with disease recurrence after radical nephroureterectomyLuis A Kluth, Evanguelos Xylinas, Matthew Kent, et al.
Pageof 21